Works matching DE "MONOCLONAL antibodies"

Results: 5000
    1
    2

    Recibokibart, an anti‐IL‐36 receptor monoclonal antibody, for treating generalized pustular psoriasis: Phase 1b trial.

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2025, v. 39, n. 6, p. e544, doi. 10.1111/jdv.20511
    By:
    • Qian, Qiaoxia;
    • Yang, Baoqi;
    • Lu, Xueyan;
    • Zhang, Zhaoxia;
    • Chen, Jiaqi;
    • Kuang, Yehong;
    • Zhang, Chunlei;
    • Man, Xiaoyong;
    • Su, Juan;
    • Ma, Chi;
    • Zhou, Guodong;
    • Li, Benke;
    • Situ, Xiaolu;
    • Ma, Xiuqiang;
    • Yang, Yongming;
    • Feng, Yujie;
    • Chen, Shi;
    • Zhan, Yifan;
    • Chen, Qian;
    • Zhu, Xiangyang
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26

    Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis).

    Published in:
    Dermatology & Therapy, 2025, v. 15, n. 6, p. 1427, doi. 10.1007/s13555-025-01416-z
    By:
    • Valenti, Mario;
    • Ibba, Luciano;
    • Di Giulio, Sara;
    • Gargiulo, Luigi;
    • Malagoli, Piergiorgio;
    • Balato, Anna;
    • Bardazzi, Federico;
    • Loconsole, Francesco;
    • Burlando, Martina;
    • Cagni, Anna E.;
    • Cameli, Norma;
    • Carrera, Carlo G.;
    • Carugno, Andrea;
    • Cuccia, Aldo;
    • Dapavo, Paolo;
    • Di Brizzi, Eugenia V.;
    • Dini, Valentina;
    • Fargnoli, Maria C.;
    • Gaiani, Francesca M.;
    • Guarneri, Claudio
    Publication type:
    Article
    27
    28
    29
    30
    31

    IQ Survey Results on Current Industry Practices—Part 1: Immunogenicity Risk Assessment.

    Published in:
    Clinical Pharmacology & Therapeutics, 2025, v. 117, n. 6, p. 1596, doi. 10.1002/cpt.3568
    By:
    • Grimaldi, Christine;
    • Richards, Susan;
    • Baltrukonis, Daniel;
    • Sims Belouski, Shelley;
    • Coble, Kelly;
    • Dholakiya, Sanjay L.;
    • Grudzinska‐Goebel, Joanna;
    • Kolaitis, Gerry;
    • Leu, Jocelyn H.;
    • Luo, Linlin;
    • Lowe, Stephen;
    • Niu, Tao;
    • Toft‐Hansen, Henrik;
    • Yang, Jianning;
    • Wu, Benjamin
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49

    Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).

    Published in:
    Cancers, 2025, v. 17, n. 9, p. 1443, doi. 10.3390/cancers17091443
    By:
    • Zehentmayr, Franz;
    • Feurstein, Petra;
    • Ruznic, Elvis;
    • Langer, Brigitte;
    • Grambozov, Brane;
    • Klebermass, Marisa;
    • Hochreiter, Alexandra;
    • Purevdorj, Ayurzana;
    • Gruber, Georg;
    • Minasch, Danijela;
    • Breitfelder, Barbara;
    • Steffal, Claudia;
    • Kirchhammer, Karoline;
    • Stranzl, Heidi;
    • Röder, Falk;
    • Dieckmann, Karin
    Publication type:
    Article
    50